Guangdong Jibao Pharmaceutical Technology Co., Ltd.

1) Primary objective: To evaluate the pharmacokinetic changes of the two preparations before and after the change under fasting conditions, and to obtain pharmacokinetic information of the changed preparations through relative bioavailability studies. 2) Secondary objective: To evaluate the safety of NCO-48F1 tablets and NCO-48F capsules (20 mg) in healthy subjects under fasting conditions.

Primary objective: To evaluate the anti-HBV activity of NCO-48F in patients with chronic hepatitis B who have been treated for 28 days. Secondary objectives: (1) To evaluate the safety and tolerability of multiple oral administration of NCO-48F. (2) To evaluate the pharmacokinetic characteristics of single and multiple oral administration of NCO-48F. (3) To preliminarily explore the recommended dose of NCO-48F for multiple oral administration in the Phase II clinical trial of chronic hepatitis B.

Primary objective: To evaluate the safety and tolerability of a single oral dose of NCO-48F in healthy subjects. Secondary objectives: 1. To evaluate the PK characteristics of NCO-48F and its metabolite TFV after a single oral dose of multiple doses of NCO-48F in healthy subjects. 2. To evaluate the effect of food on the PK characteristics of NCO-48F after a single dose of 20 mg in healthy subjects.